Home/ Stocks/ ABEO

Abeona Therapeutics Inc. Common Stock

ABEO XNAS

$7.24 +0.38 (+5.51%) ▲ 15-min delayed

Open

$6.97

High

$7.30

Low

$6.94

Volume

1.40M

Market Cap

$393.27M

About Abeona Therapeutics Inc. Common Stock

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 226 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$8.72M	$-17,075,000	$-0.30
Q3 2025	$0	$-5,161,000	$-0.10
Q2 2025	$400.0K	$108.83M	$2.07
Q1 2025	$0	$-12,029,000	$-0.24

Related Market News

No specific coverage for ABEO yet. Check out our latest market news or earnings calendar.

Get ABEO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Abeona Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.